Informed Consent

Informed consent is the process by which a prospective research participant voluntarily agrees to take part in a study after receiving a thorough explanation of the study's purpose, procedures, potential risks and benefits, alternatives to participation, and their right to withdraw at any time without penalty. It is an ethical obligation and, under regulations such as the US Common Rule (45 CFR 46) and FDA's rules (21 CFR 50), a legal requirement for most covered human subjects research, with specific exceptions and waivers.

Informed consent is a cornerstone of research ethics, rooted in the principle of respect for persons articulated in the Belmont Report, and it is a central requirement of the Declaration of Helsinki. It is meant to let individuals make autonomous decisions about their participation based on adequate information. Historical abuses in which research subjects were deceived, coerced, or left uninformed about risks (including the Tuskegee syphilis study, the Willowbrook hepatitis experiments, and Nazi medical experiments) led to the development of informed consent requirements that are now embedded in research regulations and guidelines in many countries, such as the US Common Rule and the EU Clinical Trials Regulation (Regulation (EU) No 536/2014). Researchers conducting studies with human participants need to understand and implement informed consent procedures that are both legally compliant and ethically sound.

The informed consent process involves several elements. First, the researcher provides information, typically in written form through a consent document, that covers the study's purpose, what participation will involve, the expected duration, any foreseeable risks or discomforts, any benefits to the participant or others, alternatives to participation, how confidentiality will be maintained, compensation if applicable, whom to contact with questions, and a statement that participation is voluntary and can be discontinued at any time. In the United States, the Common Rule (45 CFR 46.116) and FDA regulations (21 CFR 50.25) list the elements a consent must include, and under the 2018 Common Rule requirements the consent must begin with a concise and focused presentation of the key information most likely to help a prospective participant understand why they might or might not want to take part.

Second, the researcher ensures that the potential participant comprehends the information. This goes beyond simply handing over a document; it requires a conversation in which the researcher explains the study in accessible language, answers questions, and assesses understanding. For participants with limited literacy, language barriers, or cognitive impairments, additional measures such as simplified consent forms, interpreters, legally authorized representatives, or teach back methods may be necessary.

Third, the participant makes a voluntary decision free from coercion or undue influence. Particular care is needed when the researcher has a dual role (such as treating physician), when participants are in dependent relationships (such as students, prisoners, or employees), or when financial incentives are large enough to override careful consideration of risks.

Consent is documented through a signed consent form, though some studies may use alternative documentation procedures (such as, in the United States, a short form consent document signed by the participant after the required elements are presented orally in front of a witness, 45 CFR 46.117(b)(2) and 21 CFR 50.27(b)(2)) when approved by the IRB. Electronic consent (e consent) is accepted in some jurisdictions, including the United States, where joint OHRP and FDA guidance (December 2016) describes its use: digital platforms present information in multimedia formats and can capture electronic signatures. In the United States, an IRB may also waive the requirement for a signed form (though not the consent process itself) in specific cases, such as minimal risk research involving no procedures for which written consent is normally required outside the research context (45 CFR 46.117(c), 21 CFR 56.109(c)).

Informed consent is required for most research involving human participants, with specific exceptions and waivers. In the United States, an IRB may waive or alter consent under the Common Rule only when a set of conditions are all met, including that the research involves no more than minimal risk, could not practicably be carried out without the waiver or alteration, and will not adversely affect participants' rights and welfare (45 CFR 46.116(f)); FDA allows a similar waiver for minimal risk clinical investigations (21 CFR 50.22, in effect since January 22, 2024) and a separate exception for certain emergency research (21 CFR 50.24). Some activities need no consent under the Common Rule because they fall outside it: a study using only information whose source the investigator cannot readily identify does not involve human subjects, and public health surveillance activities authorized by a public health authority are not treated as research (45 CFR 46.102(l)(2)). Even when a waiver is granted, transparency and respect for participants remain paramount.

A common error is treating informed consent as a one time event completed at enrollment rather than an ongoing process that continues throughout the study. Participants should be informed of new findings that might affect their willingness to continue, changes to the protocol, and any new risks that emerge. Another mistake is using consent forms written in dense legal or scientific language that participants cannot understand. Readability testing and plain language revisions are best practice. Researchers also sometimes fail to allow adequate time for potential participants to consider their decision, particularly in clinical settings where there may be pressure to enroll quickly. Finally, neglecting to document the consent process (as opposed to merely obtaining a signature) makes it difficult to demonstrate compliance during audits or regulatory inspections.

A research team conducting a clinical trial of a new immunotherapy for advanced melanoma develops a consent form that describes the treatment protocol (infusions every three weeks for up to two years), known side effects (fatigue, rash, and potential autoimmune reactions), the 1 in 50 risk of severe immune mediated toxicity based on phase II data, the possibility of randomization to the control arm, and the availability of alternative approved therapies. A research coordinator meets with each potential participant for 30 to 45 minutes, reviews the form section by section, answers questions, and uses teach back to confirm understanding. Participants are given one week to discuss the study with family members before providing their signed consent.